The present study aimed to reduce the population disparity in TTR amyloidosis research, investigating two aspects of TTR Val122Ile pathogenicity: i) The early phenotypic manifestation of the mutation in AA carriers; ii) Whether non-coding variation in regulatory elements modulates the health status of AA carriers. The gene discussed is TTR; the disease is amyloidosis.